Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

DexCom, Inc. - Common Stock (NQ: DXCM )

80.24 +0.70 (+0.88%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about DexCom, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against DexCom, Inc. (DXCM)
From Glancy Prongay & Murray LLP
Via Business Wire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of DexCom, Inc. (DXCM) Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Dexcom's Stelo Device Brings Affordable Continuous Glucose Monitoring To Type 2 Diabetes Patients
DexCom's Stelo Glucose Biosensor System, the first over-the-counter continuous glucose monitor, is now available without a prescription. Designed for people with Type 2 diabetes and prediabetes, Stelo... 
Via Benzinga
Decoding 18 Analyst Evaluations For DexCom
Via Benzinga
Will New 'Milestone' Glucose Monitor Help Dexcom Stock Bounce Back?
The company is upbeat on its upcoming Stelo launch. The CGM is geared to people who don't use insulin. 
Via Investor's Business Daily
DXCM INVESTOR ALERT: DexCom, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
Stelo by Dexcom, the First Over-the-Counter Glucose Biosensor in the U.S., Is Now Available
From DexCom, Inc.
Via Business Wire
ROSEN, LEADING INVESTOR COUNSEL, Encourages DexCom, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DXCM
From The Rosen Law Firm PA
Via GlobeNewswire
DXCM Investor Alert: Robbins LLP Reminds DexCom Inc. Shareholders of the Securities Class Action Lawsuit
From Robbins LLP
Via Business Wire
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against DexCom, Inc. (DXCM)
From Law Offices of Howard G. Smith
Via Business Wire
NASDAQ: DXCM: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against DexCom, Inc.
From Kessler Topaz Meltzer & Check, LLP
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of DexCom, Inc. (DXCM) Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of DexCom, Inc. (DXCM) Investors
From Law Offices of Howard G. Smith
Via Business Wire
DEXCOM, INC. (NASDAQ: DXCM) INVESTOR ALERT: Investors With Losses in DexCom, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
From Bernstein Liebhard LLP
Via GlobeNewswire
Rosen Law Firm Urges DexCom, Inc. (NASDAQ: DXCM) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
DXCM INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces That DexCom, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
DEXCOM ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against DexCom, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Stockholder Notice: Robbins LLP Informs Stockholders of the Class Action Filed Against DexCom Inc.
From Robbins LLP
Via GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of DexCom
From Faruqi & Faruqi LLP
Via GlobeNewswire
Is It Time to Buy July's Worst-Performing S&P 500 Stocks?
These stocks took a dive recently, and that could spell opportunity. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
S&P 500, Nasdaq 100 Snap 8-Day Winning Streak: What Triggered Wall Street's Setback On Tuesday?
S&P 500 ended Tuesday's session with slight declines, halting its best winning streak since May 2024. Here's the latest. 
Via Benzinga
Topics Stocks
Exposures US Equities
S&P 500, Nasdaq Look To Snap Best Win Streaks Of 2024
Stocks are taking a breather, with the S&P 500 Index and Nasdaq Composite Index firmly lower this afternoon after yesterday nabbing their eighth-straight gains and best win streaks of the year. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Bragar Eagel & Squire, P.C. Is Investigating Helen of Troy, Owens & Minor, Iris Energy, and DexCom and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
S&P 500, Nasdaq 100 Extend 8-Session Winning Streak As Wall Street Jitters 'Go Poof': Monday's Key Stock Movers
Via Benzinga
Topics Stocks
Exposures US Equities
2 Unstoppable Healthcare Stocks to Buy Right Now With Less Than $200
These companies' growth paths should only be briefly interrupted by headwinds. 
Via The Motley Fool
2 Growth Stocks to Buy at a Discount
Look beyond share price at the business behind the stock, and you might find there's more for investors to consider. 
Via The Motley Fool
Large-Cap Stocks In Trouble: Here Are The 10 Worst Performers
Over the past twelve months, 10 large-cap stocks have underperformed all others. Here’s this week’s list of the top 10 worst performing large-caps. 
Via Talk Markets
S&P 500, Nasdaq 100 Mark Seventh Straight Positive Session, Strongest Week Since October 2023: Friday's Top Movers
S&P 500 and Nasdaq 100 indices gain for seventh straight day, marking best weekly performance since October 2023 on positive economic data. SPY and QQQ close with modest daily gains while DIA has best... 
Via Benzinga
Topics Stocks
Exposures US Equities
1 Growth Stock Down 43% to Buy Right Now
Here's why DexCom should be on your radar after the company's share price plunged recently. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.